About: Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
Creator	Baral, Ranu Vassiliou, Vassilios White, Madeline
Source	Medline; PMC
abstract	PURPOSE OF REVIEW: The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated. With an increasing number of COVID-19 cases worldwide, it is imperative to better understand the impact of RAAS inhibitors in hypertensive COVID patients. PubMed, Embase and the pre-print database Medrxiv were searched, and studies with data on patients on ACEi/ARB with COVID-19 were included. Random effects models were used to estimate the pooled mean difference with 95% confidence interval using Open Meta[Analyst] software. RECENT FINDINGS: A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034, p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964, p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908, p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235, p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218, p = 0.668). SUMMARY: This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11883-020-00880-6) contains supplementary material, which is available to authorized users.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1007/s11883-020-00880-6
bibo:pmid	32830286
has license	cc-by
sha1sum (hex)	4c371f82f40b3e5546c96ffba160f258629e0737
schema:url	https://doi.org/10.1007/s11883-020-00880-6
resource representing a document's title	Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
has PubMed Central identifier	PMC7443394
has PubMed identifier	32830286
schema:publication	Curr Atheroscler Rep
resource representing a document's body	covid:4c371f82f40b3e5546c96ffba160f258629e0737#body_text
is schema:about of	named entity 'The' named entity 'critical' named entity 'angiotensin-converting enzyme inhibitors' named entity 'models' named entity 'COVID' named entity 'cases' named entity 'COVID-19' named entity 'System' named entity 'RANDOM' named entity 'PRESCRIBED' named entity 'RECENT' named entity 'inhibitors' named entity 'cohort' named entity 'This' named entity 'Embase' named entity 'data' named entity 'confidence interval' named entity 'total' named entity 'hypertensive' named entity 'inhibitor' named entity 'angiotensin' named entity 'effects' named entity 'mortality' named entity 'critical' named entity 'PubMed' named entity 'COVID-19' named entity 'Within' named entity 'ACEi' named entity 'chronic' named entity 'Systematic' named entity '95% confidence interval' named entity 'ACEi' named entity 'meta-analysis' named entity 'angiotensin receptor blockers' named entity 'hypertensive' named entity 'COVID-19' named entity 'COVID-19' named entity 'comorbidities' named entity 'ACEi' named entity 'aldosterone' named entity 'coronavirus disease 2019' named entity 'ACE2' named entity 'angiotensin receptor blockers' named entity 'ACEi' named entity 'statistically significant' named entity 'controlled studies' named entity 'ACEi' named entity 'COVID-19' named entity 'hypertensive' named entity 'ITU' named entity '17 May' named entity 'COVID-19' named entity 'Brown University' named entity 'adult respiratory distress syndrome' named entity 'ACEi' named entity 'hypertensive' named entity 'hypertension' named entity 'RAAS' named entity 'cardiovascular diseases' named entity 'COVID' named entity 'RAAS' named entity 'RAAS' named entity 'Statistical heterogeneity' named entity 'SARS-COV-2' named entity 'COVID' named entity 'clinical trial' named entity 'COVID' named entity 'meta-analysis' named entity 'cardiovascular diseases' named entity 'Creative Commons licence' named entity 'Angiotensin-Converting Enzyme inhibitors' named entity 'ACEi' named entity 'ARDS' named entity 'non-invasive ventilation' named entity 'COVID' named entity 'downregulated' named entity 'SARS-CoV-2' named entity 'ACEi' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software